We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Dual Pharmacological Strategy against COVID-19: The Therapeutic Potential of Metformin and Atorvastatin.
- Authors
De Jesús-González, Luis Adrián; del Ángel, Rosa María; Palacios-Rápalo, Selvin Noé; Cordero-Rivera, Carlos Daniel; Rodríguez-Carlos, Adrián; Trujillo-Paez, Juan Valentin; Farfan-Morales, Carlos Noe; Osuna-Ramos, Juan Fidel; Reyes-Ruiz, José Manuel; Rivas-Santiago, Bruno; León-Juárez, Moisés; García-Herrera, Ana Cristina; Ramos-Cortes, Adriana Clara; López-Gándara, Erika Alejandra; Martínez-Rodríguez, Estefanía
- Abstract
Metformin (MET) and atorvastatin (ATO) are promising treatments for COVID-19. This review explores the potential of MET and ATO, commonly prescribed for diabetes and dyslipidemia, respectively, as versatile medicines against SARS-CoV-2. Due to their immunomodulatory and antiviral capabilities, as well as their cost-effectiveness and ubiquitous availability, they are highly suitable options for treating the virus. MET's effect extends beyond managing blood sugar, impacting pathways that can potentially decrease the severity and fatality rates linked with COVID-19. It can partially block mitochondrial complex I and stimulate AMPK, which indicates that it can be used more widely in managing viral infections. ATO, however, impacts cholesterol metabolism, a crucial element of the viral replicative cycle, and demonstrates anti-inflammatory characteristics that could modulate intense immune reactions in individuals with COVID-19. Retrospective investigations and clinical trials show decreased hospitalizations, severity, and mortality rates in patients receiving these medications. Nevertheless, the journey from observing something to applying it in a therapeutic setting is intricate, and the inherent diversity of the data necessitates carefully executed, forward-looking clinical trials. This review highlights the requirement for efficacious, easily obtainable, and secure COVID-19 therapeutics and identifies MET and ATO as promising treatments in this worldwide health emergency.
- Subjects
METFORMIN; COVID-19; VIRUS diseases; ATORVASTATIN; COVID-19 treatment; BLOOD sugar
- Publication
Microorganisms, 2024, Vol 12, Issue 2, p383
- ISSN
2076-2607
- Publication type
Article
- DOI
10.3390/microorganisms12020383